BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, November 23, 2024
See today's BioWorld Asia
Home
» Study shows just how far precision target ID has yet to go
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Study shows just how far precision target ID has yet to go
Sep. 18, 2019
By
Nuala Moran
No Comments
Ten targeted cancer drugs currently being tested in clinical trials involving 1,000 patients do not reach the targets at which they are aimed, according to recently published research.
BioWorld Asia
Science
Cancer